Background/Aims: Antibody-mediated rejection (AMR) is related to circulating donor-specific anti-human leukocyte antigen alloantibodies (DSAs). DSAs can be removed by apheresis, for example, double-filtration plasmapheresis (DFPP). However, DFPP removes some clotting factors (fibrinogen and factor XIII [FXIII]). Methods: This was a prospective trial including 6 DSA-mediated AMR kidney transplant recipients. Patients received 2 cycles of 3–4 consecutive DFPP sessions followed by 1 injection of rituximab (break of 4–5 days between the 2 cycles). We monitored fibrinogen and FXIII levels before and after each session of DFPP. Results: Overall, fibrinogen and FXIII levels were significantly decreased after each session, and were significantly reduced between the very first and very last sessions. In addition, we established a model that predicted fibrinogen and FXIII values after each session and after 2 cycles. Conclusion: We established a model in order to predict fibrinogen and FXIII depletion after DFPP sessions; it may help clinicians supplement fibrinogen and/or FXIII when appropriate.

Keywords:
Chronic antibody-mediated rejection, Double-filtration plasmapheresis, Factor XIII, Decrease, Fibrinogen
1.
Yeh JH, Chiu HC: Coagulation abnormalities in serial double-filtration plasmapheresis. J Clin Apher 2001; 16: 139–142.
2.
Nasu K, Hanafusa N, Nangaku M: Selective plasma exchange can reduce auto-antibodies in patients with bullous pemphigoid without affecting factor XIII and fibrinogen. J Clin Apher 2016; 32: 589–591.
3.
Ishikawa A, Itoh M, Ushlyama T, Suzuki K, Fujita K: Experience of ABO-incompatible living kidney transplantation after double filtration plasmapheresis. Clin Transplant 1998; 12: 80–83.
4.
Sawada T, Fuchinoue S, Kawase T, Kubota K, Teraoka S: Preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy and DFPP-enabled non-responders to undergo ABO-incompatible kidney transplantation. Clin Transplant 2004; 18: 254–260.
5.
Thalgahagoda S, Webb NJ, Roberts D, Birch A, Milford DV, Tavakoli A, Shenoy M: Successful ABO incompatible renal transplantation following rituximab and DFPP after failed immunoadsorption. Pediatr Transplant 2014; 18:E74–E76.
6.
Lin SM, Yeh JH, Lee CC, Chiu HC: Clearance of fibrinogen and von Willebrand factor in serial double-filtration plasmapheresis. J Clin Apher 2003; 18: 67–70.
7.
Hanafusa N, Kondo Y, Suzuki M, Nakao A, Noiri E, Fujita T: Double filtration plasmapheresis can decrease factor XIII activity. Ther Apher Dial 2007; 11: 165–170.
8.
Hanafusa N, Noiri E, Nangaku M: Differences in reduction of coagulation factor XIII (FXIII) between immunoadsorption plasmapheresis and double filtration plasmapheresis. Ther Apher Dial 2013; 17: 241–242.
9.
Hanafusa N, Hamasaki Y, Kawarasaki H, et al: The effect of different apheresis modalities on coagulation factor XIII level during antibody removal in ABO-blood type incompatible living related renal transplantation. Transfus Apher Sci 2013; 49: 254–258.
10.
Hohenstein B, Bornstein SR, Aringer M: Immunoadsorption for connective tissue disease. Atheroscler Suppl 2013; 14: 185–189.
11.
Biesenbach P, Eskandary F, Ay C, et al: Effect of combined treatment with immunoadsorption and membrane filtration on plasma ­coagulation – results of a randomized controlled crossover study. J Clin Apher 2016; 31: 29–37.
12.
Sellarés J, de Freitas DG, Mengel M, et al: Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388–399.
13.
Garces JC, Giusti S, Staffeld-Coit C, Bohorquez H, Cohen AJ, Loss GE: Antibody-mediated rejection: a review. Ochsner J 2017 Spring; 17: 46–55.
14.
An GH, Yun J, Hong YA, et al: The effect of combination therapy with rituximab and intravenous immunoglobulin on the progression of chronic antibody mediated rejection in renal transplant recipients. J Immunol Res 2014; 2014: 828732.
15.
Chung BH, Kim Y, Jeong HS, et al: Clinical outcome in patients with chronic antibody-mediated rejection treated with and without rituximab and intravenous immunoglobulin combination therapy. Transpl Immunol 2014; 31: 140–144.
16.
Kizilbash S, Claes D, Ashoor I, et al: Bortezomib in the treatment of antibody-mediated rejection in pediatric kidney transplant recipients: a multicenter midwest pediatric nephrology consortium study. Pediatr Transplant 2017; 21.
17.
Danés AF, Cuenca LG, Bueno SR, Mendarte Barrenechea L, Ronsano JB: Efficacy and tolerability of human fibrinogen concentrate administration to patients with acquired fibrinogen deficiency and active or in high-risk severe bleeding. Vox Sang 2008; 94: 221–226.
18.
Fenger-Eriksen C, Lindberg-Larsen M, Christensen AQ, Ingerslev J, Sørensen B: Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations. Br J Anaesth 2008; 101: 769–773.
19.
Kikuchi M, Itakura A, Miki A, Nishibayashi M, Ikebuchi K, Ishihara O: Fibrinogen concentrate substitution therapy for obstetric hemorrhage complicated by coagulopathy. J Obstet Gynaecol Res 2013; 39: 770–776.
20.
Casini A, de Moerloose P; Congenital Fibrinogen Disorders Group: Management of congenital quantitative fibrinogen disorders: a Delphi consensus. Haemophilia 2016; 22: 898–905.
21.
Palla R, Peyvandi F, Shapiro AD: Rare bleeding disorders: diagnosis and treatment. Blood 2015; 125: 2052–2061.
22.
Maaloul I, Medhaffer M, Louhichi N, Krichen I, Alibi S, et al: Factor XIII deficiency in south of Tunisia. Blood Coagul Fibrinolysis 2017; 28: 485–489.
23.
Kerlin BA, Inbal A, Will A, Williams M, Garly ML, et al: Recombinant factor XIII prophylaxis is safe and effective in young children with congenital factor XIII-A deficiency: international phase 3b trial results. J Thromb Haemost 2017; 15: 1601–1606.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.